Cancer is a disease of abnormal gene function. Some gene changes that lead to cancer may be inherited. Breast, ovarian, prostate, and colon are some of these cancers that are linked to a family history. The genetic mutations that cause many of the known hereditary cancer syndromes have been identified, and genetic testing can confirm whether a condition is the result of an inherited syndrome. Genetic profiling may help you or other family members in planning health care for the future.
Hereditary Cancer Syndrome
myRisk™ – Myriad’s myRisk™ is a test developed by Myriad Genetic Laboratories that measures an individual’s risk of developing hereditary cancer syndromes.
Hereditary Breast and Ovarian Cancer
BRACAnalysis® – Myriad’s BRACAnalysis® test assesses a person’s risk of developing hereditary breast or ovarian cancer based on the detection of mutations in the BRCA1 and BRCA2 genes.
Necessity of Chemotherapy
EndoPredict® – Myriad’s EndoPredict® is a prognostic 2nd generation IVD gene expression test to determine the risk of distant metastases in patients with estrogen receptor positive, HER2-negative primary breast cancer.
COLARIS® – Myriad’s COLARIS® testing assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine/endometrial cancer by detecting disease-causing mutations in the MLH1, MSH2, MSH6 and PMS2 genes.
COLARIS AP® – Myriad’s COLARIS AP® testing assesses a person’s risk of developing hereditary colorectal polyps and cancer by detecting mutations in the APC and MYH genes.
Prolaris® – Myriad’s Prolaris® is a test that measures how fast the cells in your tumor are dividing. Since you have had a biopsy, that tissue sample can be used to determine your Prolaris Score.
Melaris® – Myriad’s Melaris® is a test developed by Myriad Genetic Laboratories that measures a person’s risk of developing hereditary melanoma.
PANEXIA™ – Myriad’s PANEXIA™ is a genetic test specifically created to detect mutations in genes that result in an increased risk of pancreatic cancer, offering insight about the risk of future hereditary cancers for patients and their families.
The majority of cardiovascular disease (CVD) is caused by risk factors that can be controlled, treated or modified. However, there are some major CVD risk factors that cannot be controlled. Current risk functions evaluate characteristics which can only be identified once they appear, without considering other potential factors such as the patient’s genetic constitution. Genetic profiling may provide personalized information, enabling cardiovascular risk to be identified in a more precise manner.
Cardiac Sudden Death
SudD inCode® – Ferrer inCode’s SudD inCode® is a personalized medicine service that analyzes a patient’s genetic and clinical data to establish the presence of mutations (new or known) associated with the development of structural and arrhythmogenic heart diseases that can induce cardiac sudden death.
Coronary Artery Diseases (CAD)
Cardio inCode® – Ferrer inCode’s Cardio inCode® is a genetic test which evaluates an individual’s biomarkers related to the cardiovascular risk and helps to better establish the real cardiovascular risk of the patient.
Nearly 1 in 5 individuals suffer from mental illness. There are over 270 medications containing warnings, precautions and dosage recommendations based on specific gene variants. Two thirds of patients will not achieve complete relief from their first medication.* Emerging science has allowed Genomind to develop a test designed to assist in the safe and appropriate selection of pharmacologic treatment for individuals who suffer from mental illness. Genomind’s leading mental health genetic test was designed to unlock unique insights for your clinician to more quickly identify a personalized treatment plan to help you avoid the painful process of treatment by trial and error
Mental Illness and Brain Disorders
Genomind Professional PGx Express™ is a pharmacogenetic test designed to assist in the safe and appropriate selection of pharmacologic treatment for individuals who suffer from mental illness. The test offers guidance to help minimize the trial and error process of finding a safe and effective medication at the appropriate dose.
The test identifies patient-specific genetic markers that affect how patients may react to medications and other treatments. It is an easily administered cheek swab test that analyzes up to 24 key genes. These genes were selected based on FDA prescribing information, consensus expert guidelines, and data derived from hundreds of studies showing that variations in these genes may inform treatment decisions.
Unknown Genetic Disorders
Rare genetic disorders can go undiagnosed for years. The lack of a diagnosis can have considerable adverse effects for patients and their families, including failure to identify potential treatments, failure to recognize risk of recurrence in subsequent pregnancies, and failure to provide anticipatory guidance and prognosis. Genetic testing has proven to be effective in detecting rare variants in an individual’s genome, offering hope to individuals with previously undiagnosed or untreated rare disorders.
ACE Clinical Exome™ – Personalis ACE Clinical Exome™ test differs from many other types of genetic tests because instead of looking at only one or a few genes, the test looks at approximately 20,000 genes in the human genome to arrive at a potential genetic cause and diagnosis